2026-05-04
Enanta Pharmaceuticals, Inc
Results Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 enanta.com ↗Zelicapavir Reduces Symptom Duration and Hospitalization in a Randomized, Double-Blind, Placebo-Controlled, International, Phase 2 Trial
2026-04-07
Enanta Pharmaceuticals, Inc
Results Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 enanta.com ↗The second oral presentation will highlight new data confirming zelicapavir’s high clinical and functional barrier against antiviral resistance, generated from the Phase 2 study in pediatric patients, which was announced in September 2024.
2025-10-20
Enanta Pharmaceuticals, Inc
Results Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 enanta.com ↗The results presented demonstrate zelicapavir’s ability to shorten symptom duration in children aged 28 days to 36 months, while another presentation underscores EDP-323’s promise in post-exposure prophylaxis of RSV infection,
2025-10-07
Enanta Pharmaceuticals, Inc
Results Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 enanta.com ↗Zelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened Duration of RSV Symptoms in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial in Children 28 Days to 36 Months of Age
2025-09-29
Enanta Pharmaceuticals, Inc
Results Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults enanta.com ↗
2024-12-09
Enanta Pharmaceuticals, Inc
Results Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) enanta.com ↗The primary endpoint in Part 2 of the study, which focused on virology, showed a pronounced antiviral effect with a 1.4 log decline in viral load at Day 5 compared to placebo.
2022-09-29
Enanta Pharmaceuticals, Inc
Results Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium enanta.com ↗EDP-938 and EDP-323 displayed potent anti-RSV activity with EC50s below 30 nM and 1 nM, respectively.
2022-05-18
Enanta Pharmaceuticals, Inc
Results Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV) enanta.com ↗In this low-risk patient population which had mild, self-resolving upper respiratory tract infection, EDP-938 did not meet the primary endpoint of reduction in total symptom score compared to placebo, or the secondary antiviral endpoints.
2022-02-17
Enanta Pharmaceuticals, Inc
Results Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV) enanta.com ↗Overall, EDP-938 was generally safe and well-tolerated.
2019-10-03
Enanta Pharmaceuticals, Inc
Results New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay enanta.com ↗
2019-06-14
Enanta Pharmaceuticals, Inc
Results Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus (RSV) enanta.com ↗EDP-938 achieved highly statistically significant (p<0.001) reductions in viral load and in resolution of clinical symptoms compared to placebo
2018-10-23
Enanta Pharmaceuticals, Inc
Results Enanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus enanta.com ↗In the MAD phase, half-life ranged from 12.9 to 17.6 hours, and at doses comparable to those under study in the Phase 2a trial, mean trough levels were approximately 30x higher than the EC90 of EDP-938 against RSV-infected human cells.
2017-06-26
Enanta Pharmaceuticals, Inc
Results Enanta Announces New Data on EDP-938, a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV), at the XIX International Symposium on Respiratory Viral Infections enanta.com ↗EDP-938 demonstrated a greater than 4-log reduction in viral load in an animal model challenged with RSV virus.
2017-01-06
Enanta Pharmaceuticals, Inc
Results Enanta Pharmaceuticals Announces Highlights of Business Overview and Update on its Research and Development Programs to be Presented at the 35th Annual J.P. Morgan Healthcare Conference enanta.com ↗below the limits of detection (LOD) in animals treated with EDP-938.
Show 2 more releases